Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Dong Kwon Kim"
Filter
Filter
Article category
Keywords
Authors
Original Article
Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant Non–Small Cell Lung Cancer
Dong Kwon Kim, Jin Woo Park, Hyeon Bin Cho, Su Jin Choi, Sung Sook Lee, YeongMun Kim, Jii Bum Lee, Sun Min Lim, Mi Ra Yu, Byoung Chul Cho
Received December 23, 2025  Accepted March 18, 2026  Published online March 31, 2026  
DOI: https://doi.org/10.4143/crt.2025.1399    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC); however, the subsequent development of resistance emphasizes the necessity of overcoming this therapeutic limitation. MET amplification is one of the major resistance mechanisms in EGFR-mutant NSCLC, bypassing EGFR inhibition by activating cell survival, proliferation, and metastasis. Combining MET and EGFR TKIs is thus emerging as a promising therapeutic strategy to overcome resistance to EGFR TKIs.
Materials and Methods
This study investigated the combination of the selective MET TKI vabametkib and a third-generation EGFR TKI lazertinib in MET-amplified EGFR TKI resistance models. Inhibition of downstream signaling and cell proliferation by vabametkib plus lazertinib was evaluated in osimertinib-resistant NSCLC cell lines (HCC827-AR) and patient-derived organoid (YUO-010) by western blot and CellTiter-Glo assay.
Results
In vitro studies demonstrated that vabametkib plus lazertinib synergistically inhibited EGFR/MET phosphorylation, leading to markedly enhanced anti-proliferative effects through downstream phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase pathway blockade. To investigate the antitumor effects in vivo, we employed two patient-derived xenograft models (YHIM-1035(1) and YHIM-1053) harboring MET amplification, as characterized by whole-exome sequencing or droplet digital polymerase chain reaction. Consistent with the in vitro findings, treatment with vabametkib plus lazertinib produced pronounced suppression of tumor growth in both models through a synergistic mechanism.
Conclusion
These findings establish vabametkib plus lazertinib as a promising strategy for MET-amplified NSCLC, currently under evaluation in an ongoing phase II clinical trial (NCT05541822).

Citations

Citations to this article as recorded by  
  • Organoid models in lung cancer research: A multidimensional perspective from basic biology to precision medicine
    Ruili Zhao, Huifang Cheng, Shiyu Mei, Haoran Li, Longhua Zhang, Ya Li
    Letters in Drug Design & Discovery.2026; 23(3): 100424.     CrossRef
  • AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems
    Fuxiang Wang, Hongqian Jiang, Yan Chen, Zhe Zhang, Zhen Wang, Wei Liu, Fusheng Chi
    Journal of Oncology Pharmacy Practice.2026;[Epub]     CrossRef
  • Anlotinib combined with almonertinib reverses almonertinib resistance in lung adenocarcinoma by inhibiting the c-MET/PI3K/AKT pathway
    Dingdan Lu, Bo Peng, Weiwei Ouyang
    World Journal of Surgical Oncology.2026;[Epub]     CrossRef
  • 2,832 View
  • 113 Download
  • 3 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP